RecruitingDrug trialRetrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinibCABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included TKIs, immune checkpoint inhibitors or mTOR inhibitors.